Adjunctive lithium and anticonvulsants for the treatment of schizophrenia: what is the evidence? (Q37356492)

19 August 2017

1 reference

title

Adjunctive lithium and anticonvulsants for the treatment of schizophrenia: what is the evidence? (English)

1 reference

19 August 2017

0 references

Leslie Citrome

0 references

1 January 2009

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

19 August 2017

published in

1 reference

19 August 2017

1 reference

19 August 2017

1 reference

19 August 2017

page(s)

55-71

1 reference

Toward convergence in the medication treatment of bipolar disorder and schizophrenia

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.55

Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.55

Utilization of valproate: extent of inpatient use in the New York State Office of Mental Health.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.55

Changes in use of valproate and other mood stabilizers for patients with schizophrenia from 1994 to 1998.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.55

Changes in the treatment of acute psychosis in a German public hospital from 1998 to 2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.55

Psychotropic drug prescription in a psychiatric university hospital in Germany.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.55

Psychotropic drug use in psychiatric inpatients: recent trends and changes over time-data from the AMSP study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.55

Compelling or irrelevant? Using number needed to treat can help decide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.55

Schizophrenia, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and number needed to treat: how can CATIE inform clinicians?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.55

Carbamazepine in treatment of violent schizophrenics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.55

A double-blind study of adjunctive carbamazepine versus placebo on excited states of schizophrenic and schizoaffective disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.55

A double-blind trial of carbamazepine in negative symptom schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.55

Extended-release carbamazepine capsules as monotherapy in bipolar disorder : pooled results from two randomised, double-blind, placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.55

Effect of sodium valproate on tardive dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.55

Divalproex sodium augmentation of haloperidol in hospitalized patients with schizophrenia: clinical and economic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.55

The effect of sodium valproate on tardive dyskinesia--revisited.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.55

Randomized, placebo-controlled pilot study of divalproex sodium in the treatment of acute exacerbations of chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.55

Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.55

Risperidone alone versus risperidone plus valproate in the treatment of patients with schizophrenia and hostility

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.55

Adjunctive divalproex and hostility among patients with schizophrenia receiving olanzapine or risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.55

Adjunct divalproex or lithium to clozapine in treatment-resistant schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.55

Lower effectiveness of divalproex versus valproic acid in a prospective, quasi-experimental clinical trial involving 9,260 psychiatric admissions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.55

Comparison of the bioavailability of unequal doses of divalproex sodium extended-release formulation relative to the delayed-release formulation in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.55

A study of the safety, efficacy, and tolerability of switching from the standard delayed release preparation of divalproex sodium to the extended release formulation in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.55

Valproate: a practical review of its uses in neurological and psychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.55

Pregnancy outcome after in utero exposure to valproate : evidence of dose relationship in teratogenic effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.55

Clozapine plus lamotrigine in treatment-resistant schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.55

Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.55

Use of lamotrigine to augment clozapine in patients with resistant schizophrenia and comorbid alcohol dependence: a potent anti-craving effect?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.55

Adjunctive lamotrigine in treatment-resistant schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.55

Worsening of psychotic symptoms in schizophrenia with addition of lamotrigine: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.55

Remission of positive symptomatology of a schizophrenic psychosis after withdrawing lamotrigine: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.55

Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.55

Placebo-controlled trial of lamotrigine added to conventional and atypical antipsychotics in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.55

Lamotrigine as add-on therapy in schizophrenia: results of 2 placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.55

Lamotrigine and its applications in the treatment of epilepsy and other neurological and psychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.55

A 12-week, randomized, open-label, parallel-group trial of topiramate in limiting weight gain during olanzapine treatment in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.55

Topiramate as an adjuvant treatment with atypical antipsychotics in schizophrenic patients experiencing weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.55

Topiramate improves deficit symptoms in a patient with schizophrenia when added to a stable regimen of antipsychotic medication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.55

Effect of topiramate augmentation on two patients suffering from schizophrenia or bipolar disorder with comorbid alcohol abuse

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.55

Topiramate for refractory schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.55

Review of the use of Topiramate for treatment of psychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.55

Gabapentin's effect on agitation in severely and persistently mentally ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.55

Gabapentin in the treatment of antipsychotic-induced akathisia in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.55

Gabapentin in antipsychotic-induced tardive dyskinesia: results of 1-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.55

New medication treatment options for bipolar disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.55

A randomized double-blind pilot trial of gabapentin versus placebo to treat alcohol dependence and comorbid insomnia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.55

Oxcarbazepine in the treatment of bipolar and schizoaffective disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.55

Oxcarbazepine: clinical experience with hospitalized psychiatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.55

Oxcarbazepine as an adjunct for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.55

The interactive metabolism effect of oxcarbazepine coadministered with tricyclic antidepressant therapy for OCD symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.55

Addition of lithium to haloperidol in non-affective, antipsychotic non-responsive schizophrenia: a double blind, placebo controlled, parallel design clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.55

Lithium carbonate in chronic schizophrenia ? a brief trial of lithium carbonate added to neuroleptics for treatment of resistant schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.55

The Northwick Park "functional" psychosis study: diagnosis and treatment response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.55

Lithium addition to neuroleptic treatment in chronic schizophrenia: a randomized, double-blind, placebo-controlled, cross-over study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.55

Clozapine-induced leukopenia successfully treated with lithium

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.55

Rechallenging with clozapine following neutropenia: treatment options for refractory schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.55

Clozapine-induced neutropenia in children: management with lithium carbonate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.55

Delirium associated with lithium-quetiapine combination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.55

Atypical antipsychotics in the treatment of the persistently aggressive psychotic patient: methodological concerns

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.55

Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.55

Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.55

Clozapine alone versus clozapine and risperidone with refractory schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.55

Combined antipsychotic treatment involving clozapine and aripiprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.55

The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.55

Combined treatment of schizophrenic psychoses with haloperidol and valproate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.55

Datapoints: Use of Mood Stabilizers Among Patients With Schizophrenia, 1994-2001

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.55

Interpreting and applying the EUFEST results using number needed to treat: antipsychotic effectiveness in first-episode schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.55

Pharmacokinetics of Aripiprazole and Concomitant Carbamazepine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.55

The effect of lamotrigine augmentation of clozapine in a sample of treatment-resistant schizophrenic patients: A double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.55

21 January 2018

Identifiers

DOI

10.1586/14737175.9.1.55

1 reference

19 August 2017

1 reference